ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: FR-OR128

Probiotic Dietary Supplementation in Hemodialysis Patients: A Double-blind, Randomized, Placebo-Controlled Trial

Session Information

Category: Health Maintenance, Nutrition, and Metabolism

  • 1302 Health Maintenance, Nutrition, and Metabolism: Clinical


  • Liu, Sixiu, First Affiliated Hospital of Medicine School, Xi'an Jiaotong University, Xi'an, China
  • Jiang, Hongli, First Affiliated Hospital of Medicine School, Xi'an Jiaotong University, Xi'an, China

Recent studies have highlighted that gut microbiota is a key origin of uremic retention solutes in patients with chronic kidney disease, and is involved in triggering systemic microinflammation. The objective of this study was to evaluate the effects of probiotics on the gut microbiota profile and inflammatory markers in hemodialysis (HD) patients.


This was a randomized, double-blind, placebo-controlled study. Fifty HD patients were assigned to receive 1 of 2 treatments: probiotic (Pro0,n = 25; Enterococcus faecalis, Lactobacillus acidophilus, Bifidobacterium longum, 4 capsules each, twice daily, totally containing 30 billion colony-forming units per day) or placebo (PL0,n = 25) daily for 6 months. Blood samples and feces samples were collected at baseline and after intervention. The gut microbiota profile, inflammatory markers (IL-6, TNF-α and hs-CRP) and endotoxin were assessed.(Trial registration number NCT02929225.)


Twenty-three patients remained in the probiotic group(Pro2) and 22 in the placebo group(PL2). Compared with the placebo group, probiotics did not induce major changes in the faecal microbiome. The alpha and beta diversity of gut microbiota in probiotic group were not significantly different from placebo group(Fig.1(A)and(B)). However, according to the Linear discriminant analysis coupled with effect size measurements (LEfSe) further identified four bacterial families that significantly changed. Particularly, Family Enterococcaceae was increased, while Ruminococcaceae was reduced in probiotic group. In addition, the plasma levels of inflammatory markers and endotoxin were not affected by probiotics.


In HD patients, probiotics did not significantly induce major alterations in the fecal microbiome but several specific bacteria relative abundance were restored.


  • Government Support - Non-U.S.